ReviewAntioxidants (Basel, Switzerland)2025
Nrf2 as a Molecular Guardian of Redox Balance and Barrier Integrity in IBD.
Review in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Mulberroside A attenuates HMolecular medicine reports · 2026Article
- Microbiota-Derived Metabolites in the Epigenetic Regulation of Redox Homeostasis.Antioxidants (Basel, Switzerland) · 2026Review
- Paeonol-Loaded PLGA Nanoparticles Attenuate DMH-Induced Colorectal Carcinogenesis-Associated Oxidative Stress, Inflammation, and Cellular Dysregulation via Modulation of NRF2/HO-1 Signaling in Rats.International journal of molecular sciences · 2026Article
- Skin as a sentinel and modulator of systemic aging: a translational framework for evidence-based gerotherapeutics.GeroScience · 2026Review
- Current Perspectives on the Inflammatory Bowel Disease Pathogenesis of Microbiota and the Gut-Brain Axis, and Emerging Therapeutics.Biomedicines · 2026Review
- Activation of the Nrf2 Signaling Pathway by a Ginseng-Salvia Root-Notoginseng Composite Alleviates Ulcerative DSS-Induced Colitis via Restoring Gut Microbiota and the Intestinal Barrier.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, represents a chronic inflammatory condition of the gastrointestinal tract characterized by immune dysregulation, oxidative stress, and impaired epithelial barrier function. Among the complex molecular networks involved, the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) has emerged as a central regulator of redox balance, anti-inflammatory signaling, and mucosal homeostasis. This review provides a comprehensive overview of the pathogenic role of oxidative stress in IBD, detailing the sources and consequences of reactive oxygen species (ROS) accumulation, and the mechanisms by which Nrf2 activation counters these effects. We discuss the dual regulation of Nrf2 through Keap1-dependent and Keap1-independent pathways, its influence on epithelial integrity, immune cell polarization, microbiota composition, and its paradoxical role in IBD-associated tumorigenesis and fibrosis. Furthermore, we highlight emerging therapeutic strategies aimed at modulating Nrf2 activity via pharmacologic agents, dietary phytochemicals, and probiotics. Taken together, these insights position Nrf2 as a pivotal therapeutic target in IBD, offering new avenues for restoring epithelial resilience, mitigating chronic inflammation, and improving clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.